CN111868037B - 作为crhr2拮抗剂的稠合环状脲衍生物 - Google Patents
作为crhr2拮抗剂的稠合环状脲衍生物 Download PDFInfo
- Publication number
- CN111868037B CN111868037B CN201980019725.6A CN201980019725A CN111868037B CN 111868037 B CN111868037 B CN 111868037B CN 201980019725 A CN201980019725 A CN 201980019725A CN 111868037 B CN111868037 B CN 111868037B
- Authority
- CN
- China
- Prior art keywords
- methyl
- oxo
- chloro
- cyclohexyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Ink Jet (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862654628P | 2018-04-09 | 2018-04-09 | |
| US62/654,628 | 2018-04-09 | ||
| PCT/JP2019/015392 WO2019198692A1 (en) | 2018-04-09 | 2019-04-09 | Fused cyclic urea derivatives as crhr2 antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111868037A CN111868037A (zh) | 2020-10-30 |
| CN111868037B true CN111868037B (zh) | 2023-10-13 |
Family
ID=68164246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980019725.6A Active CN111868037B (zh) | 2018-04-09 | 2019-04-09 | 作为crhr2拮抗剂的稠合环状脲衍生物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11802120B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3774739B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7357932B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102590854B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN111868037B (cg-RX-API-DMAC10.html) |
| BR (1) | BR112020020708A8 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3094609A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2917634T3 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2020010568A (cg-RX-API-DMAC10.html) |
| TW (1) | TWI822754B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019198692A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122023023802A2 (pt) | 2015-04-29 | 2023-12-26 | Janssen Pharmaceutica Nv | Compostos azabenzimidazóis, seu uso como moduladores do receptor de ampa e composições farmacêuticas que os compreendem |
| WO2021145401A1 (en) * | 2020-01-15 | 2021-07-22 | Raqualia Pharma Inc. | Spiroheterocyclic derivatives as crhr2 antagonist |
| EP3901152A1 (en) * | 2020-04-23 | 2021-10-27 | F. Hoffmann-La Roche AG | Kv3 enhancers for the treatment of cognitive disorders |
| CR20220565A (es) * | 2020-05-06 | 2023-01-13 | Merck Sharp & Dohme Llc | Inhibidores de il4i1 y métodos de uso |
| WO2022071484A1 (en) * | 2020-09-30 | 2022-04-07 | Raqualia Pharma Inc. | 3-hydroxyoxindole derivatives as crhr2 antagonist |
| WO2022228365A1 (zh) * | 2021-04-27 | 2022-11-03 | 南京明德新药研发有限公司 | 六元杂芳并脲环的衍生物及其应用 |
| KR20250113346A (ko) * | 2024-01-17 | 2025-07-25 | 주식회사 엘지화학 | CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002100863A1 (en) * | 2001-06-12 | 2002-12-19 | Glaxo Group Limited | Corticotropin releasing factor antagonists |
| WO2006044821A1 (en) * | 2004-10-19 | 2006-04-27 | Sb Pharmco Puerto Rico Inc. | Crf receptor antagonists and methods relating thereto |
| CN101696208A (zh) * | 2004-06-25 | 2010-04-21 | 大正制药株式会社 | 环氨基取代的吡咯并嘧啶和吡咯并吡啶衍生物作为crf受体拮抗剂 |
| CN102143940A (zh) * | 2008-08-07 | 2011-08-03 | 诺瓦提斯公司 | 用作crf-1受体拮抗剂的环己基酰胺衍生物及其用途 |
| WO2011092293A2 (en) * | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| CN102753527A (zh) * | 2010-02-02 | 2012-10-24 | 诺瓦提斯公司 | 用作crf受体拮抗剂的环己基酰胺衍生物 |
| WO2013160317A2 (en) * | 2012-04-23 | 2013-10-31 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3538899A (en) * | 1998-04-30 | 1999-11-23 | Nippon Chemiphar Co. Ltd. | Condensed imidazole derivative and therapeutic agent for liver disease |
| CA2446514A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| US10166271B2 (en) | 2006-06-21 | 2019-01-01 | The Regents Of The University Of California | Methods for promoting hair growth |
-
2019
- 2019-04-09 MX MX2020010568A patent/MX2020010568A/es unknown
- 2019-04-09 CN CN201980019725.6A patent/CN111868037B/zh active Active
- 2019-04-09 TW TW108112345A patent/TWI822754B/zh active
- 2019-04-09 KR KR1020207030243A patent/KR102590854B1/ko active Active
- 2019-04-09 US US17/046,196 patent/US11802120B2/en active Active
- 2019-04-09 CA CA3094609A patent/CA3094609A1/en active Pending
- 2019-04-09 JP JP2020555239A patent/JP7357932B2/ja active Active
- 2019-04-09 ES ES19785626T patent/ES2917634T3/es active Active
- 2019-04-09 EP EP19785626.3A patent/EP3774739B1/en active Active
- 2019-04-09 WO PCT/JP2019/015392 patent/WO2019198692A1/en not_active Ceased
- 2019-04-09 BR BR112020020708A patent/BR112020020708A8/pt unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002100863A1 (en) * | 2001-06-12 | 2002-12-19 | Glaxo Group Limited | Corticotropin releasing factor antagonists |
| CN101696208A (zh) * | 2004-06-25 | 2010-04-21 | 大正制药株式会社 | 环氨基取代的吡咯并嘧啶和吡咯并吡啶衍生物作为crf受体拮抗剂 |
| WO2006044821A1 (en) * | 2004-10-19 | 2006-04-27 | Sb Pharmco Puerto Rico Inc. | Crf receptor antagonists and methods relating thereto |
| CN102143940A (zh) * | 2008-08-07 | 2011-08-03 | 诺瓦提斯公司 | 用作crf-1受体拮抗剂的环己基酰胺衍生物及其用途 |
| WO2011092293A2 (en) * | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| CN102753527A (zh) * | 2010-02-02 | 2012-10-24 | 诺瓦提斯公司 | 用作crf受体拮抗剂的环己基酰胺衍生物 |
| WO2013160317A2 (en) * | 2012-04-23 | 2013-10-31 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
Non-Patent Citations (1)
| Title |
|---|
| PURIN-8-ONESAS CORTICOTROPIN-RELEASING HORMONE(CRH-R1) RECEPTOR ANTAGONISTS;BECK,J.P.等;Bioorganic & Medicinal Chemistry Letters;第9卷(第7期);967-972 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020010568A (es) | 2020-10-22 |
| TW201945355A (zh) | 2019-12-01 |
| ES2917634T3 (es) | 2022-07-11 |
| BR112020020708A8 (pt) | 2022-10-18 |
| EP3774739A1 (en) | 2021-02-17 |
| JP7357932B2 (ja) | 2023-10-10 |
| US20210078975A1 (en) | 2021-03-18 |
| BR112020020708A2 (pt) | 2021-01-12 |
| WO2019198692A1 (en) | 2019-10-17 |
| US11802120B2 (en) | 2023-10-31 |
| CN111868037A (zh) | 2020-10-30 |
| KR102590854B1 (ko) | 2023-10-18 |
| EP3774739A4 (en) | 2021-08-25 |
| CA3094609A1 (en) | 2019-10-17 |
| JP2021521142A (ja) | 2021-08-26 |
| EP3774739B1 (en) | 2022-05-11 |
| KR20200135834A (ko) | 2020-12-03 |
| TWI822754B (zh) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7357932B2 (ja) | Crhr2拮抗薬としての縮合環状尿素誘導体 | |
| US10703748B2 (en) | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | |
| DK2651939T3 (en) | Substituted N- (1H-indazol-4-yl) imidazo [1,2-a] pyridine-3-carboxamide as Type-III-RECEPTOR-tyrosine kinase inhibitors | |
| TW202448473A (zh) | 包含sos1抑制劑及抗癌藥物的用於治療癌症之藥學組成物 | |
| JP2020514267A (ja) | Malt1阻害剤としてのピラゾール誘導体 | |
| JP2024028845A (ja) | コロニー刺激因子-1受容体(csf-1r)阻害剤 | |
| KR20180097749A (ko) | Rock의 억제제로서의 스피로헵탄 살리실아미드 및 관련 화합물 | |
| MD3448386T2 (ro) | Izochinolin-3-il carboxamide și prepararea și utilizarea acestora | |
| WO2023091726A1 (en) | Inhibitors of cyclin‑dependent kinase 12 (cdk12) | |
| WO2016011390A1 (en) | Irak4 inhibiting agents | |
| EP2970313A1 (en) | Substituted 7-azabicycles and their use as orexin receptor modulators | |
| KR20140043452A (ko) | 치환된 퀴놀린 및 이의 약제로서의 용도 | |
| JP2018521025A (ja) | Tnf活性のモジュレーターとしてのベンゾオキサジノン誘導体およびその類似体 | |
| MD3288940T2 (ro) | Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA | |
| US20240025906A1 (en) | Kinase modulators and methods of use thereof | |
| KR20210151833A (ko) | Eed 및 prc2 조절제로서 마크로사이클릭 아졸로피리딘 유도체 | |
| WO2013117645A1 (en) | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases | |
| US20240109900A1 (en) | Azabicyclic shp2 inhibitors | |
| CA2887887A1 (en) | Pyrazolopyridine derivatives as ttx-s blockers | |
| WO2021145401A1 (en) | Spiroheterocyclic derivatives as crhr2 antagonist | |
| IL325136A (en) | Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a | |
| RU2778641C2 (ru) | Производные конденсированной циклической мочевины в антагонист crhr2 | |
| TW202400612A (zh) | 作為HPK1抑制劑之四氫吡啶并[3,4-d]嘧啶化物 | |
| JP2023545256A (ja) | Crhr2拮抗薬としての3-ヒドロキシオキシインドール誘導体 | |
| HK40037565A (en) | Fused cyclic urea derivatives as crhr2 antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40037565 Country of ref document: HK |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20220421 Address after: Aichi Prefecture, Japan Applicant after: RAQUALIA PHARMA Inc. Address before: Aichi Prefecture, Japan Applicant before: RAQUALIA PHARMA Inc. Applicant before: National University Corporation Donghai National University |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |